Listed

IGC Pharma, Inc.: Form 10-Q for the period ended Dec 31, 2012

Filed with the SEC on Feb 13, 2013 and accepted by EDGAR at Feb 13, 2013, 08:05 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2012-12-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2012-10-01 to 2012-12-31$3.9mus-gaap:Revenues
Revenue9 months2012-04-01 to 2012-12-31$6.6mus-gaap:Revenues
Cost of revenue3 months2012-10-01 to 2012-12-31$3.2mus-gaap:CostOfRevenue
Cost of revenue9 months2012-04-01 to 2012-12-31$5.2mus-gaap:CostOfRevenue
Selling, general and administrative3 months2012-10-01 to 2012-12-31$153.8kus-gaap:SellingGeneralAndAdministrativeExpense
Selling, general and administrative9 months2012-04-01 to 2012-12-31$936.3kus-gaap:SellingGeneralAndAdministrativeExpense
Operating income3 months2012-10-01 to 2012-12-31$455.4kus-gaap:OperatingIncomeLoss
Operating income9 months2012-04-01 to 2012-12-31−$82.5kus-gaap:OperatingIncomeLoss
Interest expense3 months2012-10-01 to 2012-12-31$2.7kus-gaap:InterestExpense
Interest expense9 months2012-04-01 to 2012-12-31$28.9kus-gaap:InterestExpense
Income tax3 months2012-10-01 to 2012-12-31$453us-gaap:IncomeTaxExpenseBenefit
Income tax9 months2012-04-01 to 2012-12-31−$21.5kus-gaap:IncomeTaxExpenseBenefit
Net income3 months2012-10-01 to 2012-12-31$310.9kus-gaap:NetIncomeLoss
Net income9 months2012-04-01 to 2012-12-31−$360.1kus-gaap:NetIncomeLoss
Diluted EPS3 months2012-10-01 to 2012-12-31$0.01us-gaap:EarningsPerShareDiluted
Diluted EPS9 months2012-04-01 to 2012-12-31−$0.01us-gaap:EarningsPerShareDiluted
Basic EPS3 months2012-10-01 to 2012-12-31$0.01us-gaap:EarningsPerShareBasic
Basic EPS9 months2012-04-01 to 2012-12-31−$0.01us-gaap:EarningsPerShareBasic
Diluted shares (weighted)3 months2012-10-01 to 2012-12-3160,061,737 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Diluted shares (weighted)9 months2012-04-01 to 2012-12-3160,061,737 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow9 months2012-04-01 to 2012-12-31$1.3mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure9 months2012-04-01 to 2012-12-31$0us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Cash and equivalentsAt period end2012-12-31$2.1mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2012-12-31$5.6mus-gaap:AssetsCurrent
Total assetsAt period end2012-12-31$21.4mus-gaap:Assets
Current liabilitiesAt period end2012-12-31$3.9mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2012-12-31$5.8mus-gaap:Liabilities
Short-term borrowingsAt period end2012-12-31$4.6kus-gaap:ShortTermBorrowings
Shareholders' equityAt period end2012-12-31$14.6mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001185185-13-000299. Last ingested by Listed: Nov 6, 2026, 16:27 ET. Listed shows no prices and gives no investment advice.